[at noodls] – LEXINGTON, Mass., Jan. 24, 2013 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboardSee who Curis is hiring next, click here to view […]
[Business Wire] – TAIPEI, Taiwan–(BUSINESSWIRE)– PharmaEngine, Inc. (TWO: 4162) announced today the execution of a Collaboration and Research Agreement with Guangzhou BeBetter Medicine Technology Co., Ltd. (BeBetter). … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboardSee who Curis is hiring next, click here to view […]
[at noodls] – LEXINGTON, Mass., Dec. 12, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboardSee who Curis is hiring next, click here to view […]
[at noodls] – LEXINGTON, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboardSee who Curis is hiring next, click here to view […]
[at noodls] – LEXINGTON, Mass., Dec. 6, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboardSee who Curis is hiring next, click here to view […]
[at noodls] – – Phase I clinical testing of oral GDC-0917 recently completed – – Company also provides bioavailability update on CUDC-101; announces progress with CUDC-907 and Debio 0932 – – Conference call today at … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – – Company to Advance Development of Novel Oncology Therapeutics Including IAP Inhibitor GDC-0917 – – Conference Call Today at 8:30 a.m. EST – LEXINGTON, Mass., Nov. 28, 2012 (GLOBE NEWSWIRE) — Curis, … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LEXINGTON, Mass., Nov. 27, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – LEXINGTON, Mass., Oct. 30, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboard […]
[at noodls] – Conference Call Today at 9:00 am EST LEXINGTON, Mass., Nov. 6, 2012 (GLOBE NEWSWIRE) — Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule … moreView todays social media effects on CRISView the latest stocks trending across Twitter. Click to view dashboard […]
